[Drug therapy for Alzheimer's disease].
Cholinesterase inhibitors and memantine are widely used for the treatment of Alzheimer disease (AD) and other non-AD dementia worldwide. Since 2000, large scale prospective random control studies using meta-analysis have provided clinical evidence for the use of these drugs in AD and non-AD dementia. Here, we review these reports, including those on other drugs and newly developed drugs, which provide detailed clinical information for the daily management of dementia.
Shoji
Mikio
M
Department of Neurology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.
D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D016229:Amyloid beta-Peptides; D000894:Anti-Inflammatory Agents, Non-Steroidal; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D007464:Clioquinol / Q000031:analogs & derivatives; D015195:Drug Design; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D005480:Flurbiprofen; D007211:Indoles; D008559:Memantine / Q000627:therapeutic use; D015201:Meta-Analysis as Topic; D016032:Randomized Controlled Trials as Topic
C437846:AN-1792; D016229:Amyloid beta-Peptides; D000894:Anti-Inflammatory Agents, Non-Steroidal; D002800:Cholinesterase Inhibitors; D018691:Excitatory Amino Acid Antagonists; D007211:Indoles; C531955:PBT2 compound; C505522:tarenflurbil; D005480:Flurbiprofen; D007464:Clioquinol; C010119:latrepirdine; D008559:Memantine